Profile: Maxygen, Inc. focuses on the development of superior versions of validated major protein pharmaceuticals. We develop a series of technologies designed to improve specific properties of genes and proteins to create more effective therapies to treat diseases. Our portfolio of technologies include our Molecular Breeding™ directed evolution platform & PEGylation and directed glycosylation techniques. We specialize in the optimization & modification of protein pharmaceuticals. We cater to a pipeline of other human therapeutics products. Our proprietary technologies have the potential to transform the design and development of vaccines through the optimization of properties, that allow for the generation of broad as well as strong immune responses.